Mar. 29 at 3:36 PM
$KYMR Kymera Therapeutics presents results from BroADen Phase 1b AD trial of KT-621
Kymera Therapeutics announced that the positive results from the BroADen Phase 1b atopic dermatitis, AD, clinical trial of KT-621, its first-in-class, oral STAT6 degrader, were featured in a late-breaking oral presentation at the American Academy of Dermatology, AAD, Annual Meeting. The meeting is being held March 27-31, 2026, in Denver, CO. Data shared at AAD from the BroADen Phase 1b single-arm, open-label trial showed consistent impact across multiple pharmacodynamic and clinical measures evaluated in 22 patients with moderate-to-severe AD.
After 28 days of once-daily oral dosing, KT-621 demonstrated deep STAT6 degradation across both the 100 and 200 mg dose groups tested, with median reductions of 94% in skin and 98% in blood. KT-621 also showed robust reductions in disease-relevant Type 2 inflammatory biomarkers in blood, including median TARC reduction of 74% in patients with baseline levels comparable to dupilumab studies, up to 73% reduction of Eotaxin-3, up to 56% reduction of IL-31, and up to 14% reduction of IgE.
These biological effects translated into encouraging clinical activity with similar results across both dose groups. KT-621 demonstrated an overall mean 63% reduction in EASI, 29% EASI-75 and 19% vIGA-AD of 0 or 1, 49% reduction in BSA, and 40% reduction in peak pruritus NRS, reflecting improvements in both skin lesion severity and burden as well as itch. There was also an overall mean 9-point reduction in POEM, demonstrating a clinically meaningful improvement in patient-assessed disease severity. KT-621 was well tolerated with a favorable safety profile.
